| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/18/2005 | US20050181402 Immunoglobulin which specifically binds serum and glucocorticoid dependent kinase for diagnosing infection, inflammatory, kidney and liver disorders |
| 08/18/2005 | US20050181391 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 08/18/2005 | US20050181353 Stabilization of cells and biological specimens for analysis |
| 08/18/2005 | US20050181083 Diet food product |
| 08/18/2005 | US20050181082 plant extracts used as fungicides, microbiocides, bactericides or insecticides |
| 08/18/2005 | US20050181080 treatment of skin disorders by applying plant extracts and carriers such as gels, creams, tincture or aerosols; targeted at both the hyperproliferative and inflammatory aspect of autoimmune diseases |
| 08/18/2005 | US20050181072 Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 08/18/2005 | US20050181071 Reducing neurotransmission in the limbic system of the human brain as a means of treating depressive symptoms |
| 08/18/2005 | US20050181070 Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| 08/18/2005 | US20050181069 Citrate, acetate, bicarbonates of calcium, magnesium, sodium or potassium; resveratrol, green tea extract, tumeric, basil, sage, thyme, ginger, oregano, rosemary or extracts, glycyrrhiza glabra, plantago lanceolata, quercetin, glycyrrhiza, gingko biloba; for calcium metabolism; pH balance; muscle mass |
| 08/18/2005 | US20050181066 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 08/18/2005 | US20050181062 Comprises crystalline drug (azithromycin, amlodipine, cetirizine), a glyceride with an alkylate substituent (palmitate, stearate, oleate, linoleate, arachidate) , and a poloxamer |
| 08/18/2005 | US20050181061 Extrusion/melt-congeal process; reduced drug degradation |
| 08/18/2005 | US20050181060 Method of making pharmaceutical multiparticulates |
| 08/18/2005 | US20050181055 Includes a therapeutically effective amount of quinapril or an acid addition salt thereof and between about 15- 40% w/w of an alkaline substance; angiotensin-converting enzyme (ACE) inhibitor; hypertension, heart failure and angioedema |
| 08/18/2005 | US20050181054 comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm; efficient penetration and high permeability blood at the mucosa |
| 08/18/2005 | US20050181051 Contains Cefixime Trihydrate, Cloxacillin Sodium (sustained release and immediate release form), Lactobacillus sporogenes spores |
| 08/18/2005 | US20050181050 Dosage forms using drug-loaded ion exchange resins |
| 08/18/2005 | US20050181048 Compositions and methods for timed release of a water-soluble nutritional supplement, methylsulfonylmethane |
| 08/18/2005 | US20050181047 Provides a longer delay and a high concentration of a nutritional supplement whose dissolution allows greater flexibility in designing timed release profiles |
| 08/18/2005 | US20050181046 Tamper-resistant oral opioid agonist formulations |
| 08/18/2005 | US20050181045 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 08/18/2005 | US20050181043 Particle size distribution; drug package comprising a high density polyethylene bottle comprising alendronate sodium; do not require lactose or polyvinylpyrrolidone in order to achieve blend uniformity; administered as inhibitor of osteoclast-mediated bone bioresorption |
| 08/18/2005 | US20050181042 Composition for oral or rectal administration |
| 08/18/2005 | US20050181041 Forming solution of drugs, dietary supplements, and/or agrochemicals and crystal lattice modifier dissolved in a solvent; mixing with nonsolvent; crystallization; drug delivery; stability |
| 08/18/2005 | US20050181040 Progestagenic dosage unit |
| 08/18/2005 | US20050181039 Micelles |
| 08/18/2005 | US20050181038 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 08/18/2005 | US20050181037 Cardiolipin compositions their methods of preparation and use |
| 08/18/2005 | US20050181036 Lipid vehicle which can be nebulized comprising curcumin, lipids, and aqueous solvent; bioavailability; administering antiproliferative, anticarcinogenic, antiasthmatic, antiischemic, antiinflammatory and/or antibiotic agents; respiratory, neurodegenerative, brain, autoimmune, and rheumatic diseases |
| 08/18/2005 | US20050181034 3-Amidino- or 3-guanidino phenylalanine derivative which is effective as urokinase inhibitor; antitumor, anticarcinogenic, and antimetastasis agents |
| 08/18/2005 | US20050181032 Metastable pharmaceutical compositions |
| 08/18/2005 | US20050181031 Permeation enhancer comprising fatty acid ester and/or a terpene; urogenital and respiratory system disorders |
| 08/18/2005 | US20050181030 Topical stabilized prostaglandin E compound dosage forms |
| 08/18/2005 | US20050181028 Topical composition and method for treating occlusive wounds |
| 08/18/2005 | US20050181026 Lactate and glucose supply; 2-acrylamido-2-methylpropanesulfonic acid, sodium salt (Lubrizol), polyoxyethylene glycol diacrylate, photoinitiator of 1-hydroxycyclohexyl phenyl ketone, glucose, zinc lactate, potassium iodide, and deionized water; wound healing agents |
| 08/18/2005 | US20050181025 Physiologically acceptable salt of hyaluronic acid, iodine and potassium iodine; disinfects wound and reduces infection, removes secretions thereby reducing maceration, maintains wound hydration, and enhances granulation and epithelial cell formation of wounded tissue |
| 08/18/2005 | US20050181021 Liposomes in food, beverage, or nutritional supplement; prophylaxis; encapsulated, sonicated |
| 08/18/2005 | US20050181018 Ocular drug delivery |
| 08/18/2005 | US20050181017 Compositions and methods for localized therapy of the eye |
| 08/18/2005 | US20050180982 Assessing metastatic potential of carcinoma cells by contacting cells in tissue sample suspected of containing carcinoma with detectable indicator capable of binding to cad-11 or cad-11 mRNA and determining presence or absence of cad-11 expression in tissue; method of preventing or terminating pregnancy |
| 08/18/2005 | US20050180975 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 08/18/2005 | US20050180973 TREM-1 splice variant for use in modifying immune responses |
| 08/18/2005 | US20050180971 Cancer therapy |
| 08/18/2005 | US20050180965 Heat-reversible composition treating hyposalia and asialia |
| 08/18/2005 | US20050180964 Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
| 08/18/2005 | US20050180962 treating a non-alcoholic fatty liver disease; inactivated probiotic bacteria; and a pharmaceutically acceptable excipient; gastrointestinal inflammation; allergic asthma |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |
| 08/18/2005 | US20050180956 SSAO enzyme substrates for vasorelaxation, and methods of use thereof |
| 08/18/2005 | US20050180955 gene therapy; delivering recombinant adeno-associated virus virions to the brain; pumping; transgene encodes an aromatic amino acid decarboxylase |
| 08/18/2005 | US20050180953 peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[N-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (Dicarbamine (reg) ) |
| 08/18/2005 | US20050180952 agent has a higher tissue bioavailability in a particular tissue; benefits and improvements over conventional drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival |
| 08/18/2005 | US20050180946 such as triethanolamine with 2 hydroxyethyl groups derivatized with polyethylene glycol, and the amine group conjugated to drugs such as antitumor agent interferon |
| 08/18/2005 | US20050180945 glycopolymers, useful for biomolecular recognition processes which can be immobilized onto surfaces; easily synthesized; sulfated glycopolymers which are useful for reducing blood coagulation; for providing surfaces capable of binding to bioactive molecules for use in bio and immunochemical assays |
| 08/18/2005 | US20050180926 Inhalable aerosol medicament for the treatment or prevention of pain |
| 08/18/2005 | US20050180925 Formulations and methods for treating rhinosinusitis |
| 08/18/2005 | US20050180924 Composition and method for moisturizing nasal tissue |
| 08/18/2005 | US20050178396 Polymer compositions and methods for their use |
| 08/18/2005 | US20050178395 Polymer compositions and methods for their use |
| 08/18/2005 | DE3933164B4 Prepn. for iron supply - comprises specified amts. of specified iron contg. cpd., sodium carbonate or bi:carbonate and a neutralising agent |
| 08/18/2005 | DE10360954B3 Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen Use of silibinin, its salts and / or its prodrugs together with α-lipoic acid for the treatment of chronic obstructive pulmonary disease |
| 08/18/2005 | DE102004022746A1 Side-effect free thrombolytic tablets for combating disposition towards thromboembolism, containing acetylsalicylic acid and dry extracts of melilot, horse chestnut seed and butcher's broom root |
| 08/18/2005 | DE102004005172A1 Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase Indazole derivatives as inhibitors of hormone sensitive lipase |
| 08/18/2005 | DE102004005106A1 New furanone and bicyclooctane derivatives, e.g. sorbifuranone A, B or C, sorbivinetone and sorbivinetol, useful as antitumor agents, prepared e.g. by culturing Penicillium fungi |
| 08/18/2005 | DE102004004974A1 Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen Thieno-imino acid derivatives as inhibitors of matrix metalloproteinases |
| 08/18/2005 | DE102004004969A1 UV-light-protective filters are used in reducing microcomedones or (optionally together with hydroxy-acids) in increasing the therapeutic effectiveness in acne treatment |
| 08/18/2005 | DE102004004928A1 Dibenzoxazepine II Dibenzoxazepines II |
| 08/18/2005 | DE102004002885A1 New pyrrole alkaloid daminin and its derivatives, are intracellular calcium ion concentration reducing neuroprotective agents useful for treating neurodegenerative diseases, e.g. Alzheimer's disease |
| 08/18/2005 | DE102004002884A1 New aspernigrin B derivatives are intracellular calcium ion concentration reducing neuroprotective agents, useful for treating neurodegenerative diseases e.g. Parkinson's disease and multiple sclerosis |
| 08/18/2005 | DE102004002638A1 Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten Combinations of serotonin reuptake inhibitors and imidazoline I2 agonists |
| 08/18/2005 | DE102004001558A1 Arzneimittel zur topischen Applikation bei Tieren Drugs for topical application in animals |
| 08/18/2005 | DE10134196B4 Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen A pharmaceutical composition for inhibiting uncontrolled proliferation and / or inducing apoptosis of cells |
| 08/18/2005 | DE10008159B4 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or their physiologically acceptable salts as an anti-cancer agent |
| 08/18/2005 | CA2558877A1 Solifenacin succinate-containing composition |
| 08/18/2005 | CA2556181A1 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
| 08/18/2005 | CA2555632A1 Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure |
| 08/18/2005 | CA2555491A1 Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof |
| 08/18/2005 | CA2555486A1 Compositions containing cis-isomers of a carotenoid compound and process |
| 08/18/2005 | CA2555463A1 Inhibitors of tgf-r signaling for treatment of cns disorders |
| 08/18/2005 | CA2555328A1 Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
| 08/18/2005 | CA2555316A1 Combined pharmaceutical composition |
| 08/18/2005 | CA2555311A1 Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands |
| 08/18/2005 | CA2555308A1 Thiazolylimidazole derivatives and their use as inhibitors of microsomal triglyceride transfer protein |
| 08/18/2005 | CA2555304A1 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome |
| 08/18/2005 | CA2555296A1 Composition of labdane diterpenes extracted from andrographis paniculata, useful for the treatment of autoimmune diseases, and alzheimer disease by activation of ppr-gamma receptors |
| 08/18/2005 | CA2555262A1 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| 08/18/2005 | CA2555199A1 Peptidylarginine deiminase 4 inhibitor |
| 08/18/2005 | CA2555083A1 Genes associated with canine osteoarthritis and related methods and compositions |
| 08/18/2005 | CA2555033A1 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |
| 08/18/2005 | CA2554975A1 Methods of preventing and treating sars using low ph respiratory tract compositions |
| 08/18/2005 | CA2554927A1 Stable amorphous forms of montelukast sodium |
| 08/18/2005 | CA2554892A1 Flat system for using in the oral cavity |
| 08/18/2005 | CA2554809A1 Novel n-alkyl thiourea-and thioamide-substituted imidazolyl inhibitors and glutaminyl cyclase |
| 08/18/2005 | CA2554789A1 Montelukast sodium polymorphs |
| 08/18/2005 | CA2554775A1 Naphthalimide dosing by n-acetyl transferase genotyping |
| 08/18/2005 | CA2554705A1 Alpha-4 integrin mediated cell adhesion inhibitors for the treatment or prevention of inflammatory diseases |
| 08/18/2005 | CA2554671A1 Chemokine ccr5 receptor modulators |
| 08/18/2005 | CA2554632A1 Method of treating hemolytic disease |
| 08/18/2005 | CA2554628A1 Methods of modulating cd200 and cd200r |
| 08/18/2005 | CA2554620A1 Pyrazoloacrydone derivative-containing solution |